[1]
|
NUCLEOTIDE SEQUENCE [MRNA].
PubMed=4006916 [NCBI, ExPASy, EBI, Israel, Japan]
Zakut-Houri R.,
Bienz-Tadmor B.,
Givol D.,
Oren M.;
"Human p53 cellular tumor antigen: cDNA sequence and expression in COS cells.";
EMBO J. 4:1251-1255(1985).
|
[2]
|
NUCLEOTIDE SEQUENCE [GENOMIC DNA / MRNA].
PubMed=2946935 [NCBI, ExPASy, EBI, Israel, Japan]
Lamb P.,
Crawford L.;
"Characterization of the human p53 gene.";
Mol. Cell. Biol. 6:1379-1385(1986).
|
[3]
|
NUCLEOTIDE SEQUENCE [MRNA].
PubMed=3894933 [NCBI, ExPASy, EBI, Israel, Japan]
Harlow E.,
Williamson N.M.,
Ralston R.,
Helfman D.M.,
Adams T.E.;
"Molecular cloning and in vitro expression of a cDNA clone for human cellular tumor antigen p53.";
Mol. Cell. Biol. 5:1601-1610(1985).
|
[4]
|
NUCLEOTIDE SEQUENCE [MRNA].
PubMed=3025664 [NCBI, ExPASy, EBI, Israel, Japan]
Harris N.,
Brill E.,
Shohat O.,
Prokocimer M.,
Wolf D.,
Arai N.,
Rotter V.;
"Molecular basis for heterogeneity of the human p53 protein.";
Mol. Cell. Biol. 6:4650-4656(1986).
|
[5]
|
NUCLEOTIDE SEQUENCE [GENOMIC DNA].
DOI=10.1016/0378-1119(88)90196-5; PubMed=2905688 [NCBI, ExPASy, EBI, Israel, Japan]
Buchman V.L.,
Chumakov P.M.,
Ninkina N.N.,
Samarina O.P.,
Georgiev G.P.;
"A variation in the structure of the protein-coding region of the human p53 gene.";
Gene 70:245-252(1988).
|
[6]
|
NUCLEOTIDE SEQUENCE [GENOMIC DNA / MRNA] OF 101-393.
PubMed=6396087 [NCBI, ExPASy, EBI, Israel, Japan]
Matlashewski G.,
Lamb P.,
Pim D.,
Peacock J.,
Crawford L.,
Benchimol S.;
"Isolation and characterization of a human p53 cDNA clone: expression of the human p53 gene.";
EMBO J. 3:3257-3262(1984).
|
[7]
|
NUCLEOTIDE SEQUENCE [MRNA], VARIANTS BURKITT LYMPHOMA, AND VARIANT ARG-72.
PubMed=1915267 [NCBI, ExPASy, EBI, Israel, Japan]
Farrell P.J.,
Allan G.,
Shanahan F.,
Vousden K.H.,
Crook T.;
"p53 is frequently mutated in Burkitt's lymphoma cell lines.";
EMBO J. 10:2879-2887(1991).
|
[8]
|
NUCLEOTIDE SEQUENCE [GENOMIC DNA], AND VARIANTS ARG-72 AND LYS-286.
PubMed=8316628 [NCBI, ExPASy, EBI, Israel, Japan]
Allalunis-Turner M.J.,
Barron G.M.,
Day R.S. III,
Dobler K.D.,
Mirzayans R.;
"Isolation of two cell lines from a human malignant glioma specimen differing in sensitivity to radiation and chemotherapeutic drugs.";
Radiat. Res. 134:349-354(1993).
|
[9]
|
NUCLEOTIDE SEQUENCE [MRNA], VARIANT ARG-72, AND INTERACTION WITH WWOX.
DOI=10.1074/jbc.M007140200; PubMed=11058590 [NCBI, ExPASy, EBI, Israel, Japan]
Chang N.-S.,
Pratt N.,
Heath J.,
Schultz L.,
Sleve D.,
Carey G.B.,
Zevotek N.;
"Hyaluronidase induction of a WW domain-containing oxidoreductase that enhances tumor necrosis factor cytotoxicity.";
J. Biol. Chem. 276:3361-3370(2001).
|
[10]
|
NUCLEOTIDE SEQUENCE [GENOMIC DNA].
Chumakov P.M.,
Almazov V.P.,
Jenkins J.R.;
Submitted (JUN-1991) to the EMBL/GenBank/DDBJ databases.
|
[11]
|
NUCLEOTIDE SEQUENCE [GENOMIC DNA].
Rozemuller E.H.,
Tilanus M.G.J.;
"P53 genomic sequence. Corrections and polymorphism.";
Submitted (MAR-1997) to the EMBL/GenBank/DDBJ databases.
|
[12]
|
NUCLEOTIDE SEQUENCE [GENOMIC DNA], AND VARIANTS SER-47; ARG-72; LYS-339 AND ALA-366.
Livingston R.J.,
Rieder M.J.,
Chung M.-W.,
Ritchie T.K.,
Olson A.N.,
Nguyen C.P.,
Gildersleeve H.,
Cassidy C.M.,
Johnson E.J.,
Swanson J.E.,
McFarland I.,
Yool B.,
Park C.,
Nickerson D.A.;
"NIEHS-SNPs, environmental genome project, NIEHS ES15478, Department of Genome Sciences, Seattle, WA (URL: http://egp.gs.washington.edu).";
Submitted (NOV-2004) to the EMBL/GenBank/DDBJ databases.
|
[13]
|
NUCLEOTIDE SEQUENCE [GENOMIC DNA], AND VARIANTS ARG-72 AND LYS-286.
PubMed=11023613 [NCBI, ExPASy, EBI, Israel, Japan]
Anderson C.W.,
Allalunis-Turner M.J.;
"Human TP53 from the malignant glioma-derived cell lines M059J and M059K has a cancer-associated mutation in exon 8.";
Radiat. Res. 154:473-476(2000).
|
[14]
|
NUCLEOTIDE SEQUENCE [MRNA], AND VARIANTS ARG-72; HIS-273 AND SER-309.
Azuma K.,
Shichijo S.,
Itoh K.;
"Identification of a tumor-rejection antigen recognized by HLA-B46 restricted CTL.";
Submitted (MAR-2002) to the EMBL/GenBank/DDBJ databases.
|
[15]
|
NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA], AND VARIANTS ARG-72 AND ALA-278.
TISSUE=Kidney;
DOI=10.1101/gr.2596504; PubMed=15489334 [NCBI, ExPASy, EBI, Israel, Japan]
The MGC Project Team;
"The status, quality, and expansion of the NIH full-length cDNA project: the Mammalian Gene Collection (MGC).";
Genome Res. 14:2121-2127(2004).
|
[16]
|
NUCLEOTIDE SEQUENCE [MRNA] OF 1-379, AND VARIANTS ARG-72 AND ASN-139.
TISSUE=Lung carcinoma;
DOI=10.1073/pnas.2536558100; PubMed=14660794 [NCBI, ExPASy, EBI, Israel, Japan]
Kanashiro C.A.,
Schally A.V.,
Groot K.,
Armatis P.,
Bernardino A.L.,
Varga J.L.;
"Inhibition of mutant p53 expression and growth of DMS-153 small cell lung carcinoma by antagonists of growth hormone-releasing hormone and bombesin.";
Proc. Natl. Acad. Sci. U.S.A. 100:15836-15841(2003).
|
[17]
|
NUCLEOTIDE SEQUENCE [GENOMIC DNA] OF 126-185.
Pan X.L.,
Zhang A.H.;
"Study on the effect of tumor suppressor gene p53 in arsenism patients.";
Submitted (SEP-2003) to the EMBL/GenBank/DDBJ databases.
|
[18]
|
NUCLEOTIDE SEQUENCE [GENOMIC DNA] OF 261-298.
TISSUE=Blood;
Nimri L.F.,
Owais W.,
Momani E.;
"Detection of P53 gene mutations and serum p53 antibodies associated with cigarette smoking.";
Submitted (AUG-2003) to the EMBL/GenBank/DDBJ databases.
|
[19]
|
NUCLEOTIDE SEQUENCE [GENOMIC DNA] OF 262-306.
TISSUE=Ovarian adenocarcinoma;
Filippini G.,
Soldati G.;
Submitted (JUL-1996) to the EMBL/GenBank/DDBJ databases.
|
[20]
|
NUCLEOTIDE SEQUENCE [GENOMIC DNA] OF 225-260.
TISSUE=Glial cell, and Glial tumor;
Thompson-Hehir J.,
Davies M.P.A.,
Green J.A.,
Halliwell N.,
Joyce K.A.,
Salisbury J.,
Sibson D.R.,
Vergote I.,
Walker C.;
"Mutation detection utilizing a novel PCR approach for amplification of the p53 gene from microdissected tissue: application to archival tumor samples.";
Submitted (DEC-1999) to the EMBL/GenBank/DDBJ databases.
|
[21]
|
NUCLEOTIDE SEQUENCE [GENOMIC DNA] OF 225-260.
Yavuz A.S.,
Farner N.L.,
Yavuz S.,
Grammer A.C.,
Girschick H.J.,
Lipsky P.E.;
"Bcl6 and P53 gene mutations in tonsillar B cells.";
Submitted (MAR-2000) to the EMBL/GenBank/DDBJ databases.
|
[22]
|
NUCLEOTIDE SEQUENCE [GENOMIC DNA] OF 332-366.
Pinto E.M.,
Mendonca B.B.,
Latronico A.C.;
"Allelic variant in intron 9 of TP53 gene.";
Submitted (APR-2003) to the EMBL/GenBank/DDBJ databases.
|
[23]
|
RNA-BINDING.
PubMed=1705009 [NCBI, ExPASy, EBI, Israel, Japan]
Samad A.,
Carroll R.B.;
"The tumor suppressor p53 is bound to RNA by a stable covalent linkage.";
Mol. Cell. Biol. 11:1598-1606(1991).
|
[24]
|
ALTERNATIVE SPLICING.
PubMed=8632903 [NCBI, ExPASy, EBI, Israel, Japan]
Flaman J.-M.,
Waridel F.,
Estreicher A.,
Vannier A.,
Limacher J.-M.,
Gilbert D.,
Iggo R.,
Frebourg T.;
"The human tumour suppressor gene p53 is alternatively spliced in normal cells.";
Oncogene 12:813-818(1996).
|
[25]
|
NUCLEAR LOCALIZATION SIGNAL.
PubMed=2156209 [NCBI, ExPASy, EBI, Israel, Japan]
Addison C.,
Jenkins J.R.,
Sturzbecher H.-W.;
"The p53 nuclear localisation signal is structurally linked to a p34cdc2 kinase motif.";
Oncogene 5:423-426(1990).
|
[26]
|
INTERACTION WITH E4F1.
DOI=10.1038/sj.onc.1203250; PubMed=10644996 [NCBI, ExPASy, EBI, Israel, Japan]
Sandy P.,
Gostissa M.,
Fogal V.,
Cecco L.D.,
Szalay K.,
Rooney R.J.,
Schneider C.,
Del Sal G.;
"p53 is involved in the p120E4F-mediated growth arrest.";
Oncogene 19:188-199(2000).
|
[27]
|
MINIMAL REPRESSION DOMAIN.
DOI=10.1074/jbc.M008231200; PubMed=11007800 [NCBI, ExPASy, EBI, Israel, Japan]
Hong T.M.,
Chen J.J.,
Peck K.,
Yang P.C.,
Wu C.W.;
"p53 amino acids 339-346 represent the minimal p53 repression domain.";
J. Biol. Chem. 276:1510-1515(2001).
|
[28]
|
INTERACTION WITH ING4.
PubMed=12750254 [NCBI, ExPASy, EBI, Israel, Japan]
Shiseki M.,
Nagashima M.,
Pedeux R.M.,
Kitahama-Shiseki M.,
Miura K.,
Okamura S.,
Onogi H.,
Higashimoto Y.,
Appella E.,
Yokota J.,
Harris C.C.;
"p29ING4 and p28ING5 bind to p53 and p300, and enhance p53 activity.";
Cancer Res. 63:2373-2378(2003).
|
[29]
|
PHOSPHORYLATION BY P60/CDC2 AND CYCLIN B/CDC2.
PubMed=2141171 [NCBI, ExPASy, EBI, Israel, Japan]
Bischoff J.R.,
Friedman P.N.,
Marshak D.R.,
Prives C.,
Beach D.;
"Human p53 is phosphorylated by p60-cdc2 and cyclin B-cdc2.";
Proc. Natl. Acad. Sci. U.S.A. 87:4766-4770(1990).
|
[30]
|
DEPHOSPHORYLATION BY PP2A.
PubMed=1848668 [NCBI, ExPASy, EBI, Israel, Japan]
Scheidtmann K.H.,
Mumby M.C.,
Rundell K.,
Walter G.;
"Dephosphorylation of simian virus 40 large-T antigen and p53 protein by protein phosphatase 2A: inhibition by small-t antigen.";
Mol. Cell. Biol. 11:1996-2003(1991).
|
[31]
|
O-GLYCOSYLATION.
PubMed=8632915 [NCBI, ExPASy, EBI, Israel, Japan]
Shaw P.,
Freeman J.,
Bovey R.,
Iggo R.;
"Regulation of specific DNA binding by p53: evidence for a role for O-glycosylation and charged residues at the carboxy-terminus.";
Oncogene 12:921-930(1996).
|
[32]
|
PHOSPHORYLATION AT THR-18.
DOI=10.1038/sj.onc.1203709; PubMed=10951572 [NCBI, ExPASy, EBI, Israel, Japan]
Lopez-Borges S.,
Lazo P.A.;
"The human vaccinia-related kinase 1 (VRK1) phosphorylates threonine-18 within the mdm-2 binding site of the p53 tumour suppressor protein.";
Oncogene 19:3656-3664(2000).
|
[33]
|
ACETYLATION AT LYS-373 AND LYS-382.
DOI=10.1006/jmbi.1999.3415; PubMed=10656795 [NCBI, ExPASy, EBI, Israel, Japan]
Abraham J.,
Kelly J.,
Thibault P.,
Benchimol S.;
"Post-translational modification of p53 protein in response to ionizing radiation analyzed by mass spectrometry.";
J. Mol. Biol. 295:853-864(2000).
|
[34]
|
DEACETYLATION AT LYS-382 BY SIRT1.
DOI=10.1016/S0092-8674(01)00527-X; PubMed=11672523 [NCBI, ExPASy, EBI, Israel, Japan]
Vaziri H.,
Dessain S.K.,
Ng Eaton E.,
Imai S.,
Frye R.A.,
Pandita T.K.,
Guarente L.,
Weinberg R.A.;
"hSIR2(SIRT1) functions as an NAD-dependent p53 deacetylase.";
Cell 107:149-159(2001).
|
[35]
|
PHOSPHORYLATION BY PRPK.
DOI=10.1074/jbc.M105669200; PubMed=11546806 [NCBI, ExPASy, EBI, Israel, Japan]
Abe Y.,
Matsumoto S.,
Wei S.,
Nezu K.,
Miyoshi A.,
Kito K.,
Ueda N.,
Shigemoto K.,
Hitsumoto Y.,
Nikawa J.,
Enomoto Y.;
"Cloning and characterization of a p53-related protein kinase expressed in interleukin-2-activated cytotoxic T-cells, epithelial tumor cell lines, and the testes.";
J. Biol. Chem. 276:44003-44011(2001).
|
[36]
|
PHOSPHORYLATION AT SER-392.
DOI=10.1016/S1097-2765(01)00176-9; PubMed=11239457 [NCBI, ExPASy, EBI, Israel, Japan]
Keller D.M.,
Zeng X.,
Wang Y.,
Zhang Q.H.,
Kapoor M.,
Shu H.,
Goodman R.,
Lozano G.,
Zhao Y.,
Lu H.;
"A DNA damage-induced p53 serine 392 kinase complex contains CK2, hSpt16, and SSRP1.";
Mol. Cell 7:283-292(2001).
|
[37]
|
INTERACTION WITH USP7.
DOI=10.1016/S0092-8674(02)01199-6; PubMed=12507430 [NCBI, ExPASy, EBI, Israel, Japan]
Hu M.,
Li P.,
Li M.,
Li W.,
Yao T.,
Wu J.-W.,
Gu W.,
Cohen R.E.,
Shi Y.;
"Crystal structure of a UBP-family deubiquitinating enzyme in isolation and in complex with ubiquitin aldehyde.";
Cell 111:1041-1054(2002).
|
[38]
|
IDENTIFICATION IN A COMPLEX WITH CABLES1 AND TP73.
DOI=10.1074/jbc.M108535200; PubMed=11706030 [NCBI, ExPASy, EBI, Israel, Japan]
Tsuji K.,
Mizumoto K.,
Yamochi T.,
Nishimoto I.,
Matsuoka M.;
"Differential effect of ik3-1/cables on p53- and p73-induced cell death.";
J. Biol. Chem. 277:2951-2957(2002).
|
[39]
|
INTERACTION WITH HIPK2.
DOI=10.1074/jbc.M200153200; PubMed=11925430 [NCBI, ExPASy, EBI, Israel, Japan]
Kim E.-J.,
Park J.-S.,
Um S.-J.;
"Identification and characterization of HIPK2 interacting with p73 and modulating functions of the p53 family in vivo.";
J. Biol. Chem. 277:32020-32028(2002).
|
[40]
|
INTERACTION WITH HIPK2, PHOSPHORYLATION AT SER-46, AND MUTAGENESIS OF SER-46 AND LYS-382.
DOI=10.1038/ncb715; PubMed=11740489 [NCBI, ExPASy, EBI, Israel, Japan]
Hofmann T.G.,
Moeller A.,
Sirma H.,
Zentgraf H.,
Taya Y.,
Droege W.,
Will H.,
Schmitz M.L.;
"Regulation of p53 activity by its interaction with homeodomain-interacting protein kinase-2.";
Nat. Cell Biol. 4:1-10(2002).
|
[41]
|
INTERACTION WITH HIPK2, AND PHOSPHORYLATION AT SER-46.
DOI=10.1038/ncb714; PubMed=11780126 [NCBI, ExPASy, EBI, Israel, Japan]
D'Orazi G.,
Cecchinelli B.,
Bruno T.,
Manni I.,
Higashimoto Y.,
Saito S.,
Gostissa M.,
Coen S.,
Marchetti A.,
Del Sal G.,
Piaggio G.,
Fanciulli M.,
Appella E.,
Soddu S.;
"Homeodomain-interacting protein kinase-2 phosphorylates p53 at Ser 46 and mediates apoptosis.";
Nat. Cell Biol. 4:11-19(2002).
|
[42]
|
ACETYLATION AT LYS-305.
DOI=10.1074/jbc.M212574200; PubMed=12724314 [NCBI, ExPASy, EBI, Israel, Japan]
Wang Y.H.,
Tsay Y.G.,
Tan B.C.,
Lo W.Y.,
Lee S.C.;
"Identification and characterization of a novel p300-mediated p53 acetylation site, lysine 305.";
J. Biol. Chem. 278:25568-25576(2003).
|
[43]
|
INTERACTION WITH P53DINP1.
DOI=10.1074/jbc.M301979200; PubMed=12851404 [NCBI, ExPASy, EBI, Israel, Japan]
Tomasini R.,
Samir A.A.,
Carrier A.,
Isnardon D.,
Cecchinelli B.,
Soddu S.,
Malissen B.,
Dagorn J.-C.,
Iovanna J.L.,
Dusetti N.J.;
"TP53INP1s and homeodomain-interacting protein kinase-2 (HIPK2) are partners in regulating p53 activity.";
J. Biol. Chem. 278:37722-37729(2003).
|
[44]
|
NUCLEOCYTOPLASMIC SHUTTLING, AND NUCLEAR EXPORT SIGNAL.
DOI=10.1128/MCB.23.18.6396-6405.2003; PubMed=12944468 [NCBI, ExPASy, EBI, Israel, Japan]
O'Keefe K.,
Li H.,
Zhang Y.;
"Nucleocytoplasmic shuttling of p53 is essential for MDM2-mediated cytoplasmic degradation but not ubiquitination.";
Mol. Cell. Biol. 23:6396-6405(2003).
|
[45]
|
INTERACTION WITH HIPK1.
DOI=10.1073/pnas.0530308100; PubMed=12702766 [NCBI, ExPASy, EBI, Israel, Japan]
Kondo S.,
Lu Y.,
Debbas M.,
Lin A.W.,
Sarosi I.,
Itie A.,
Wakeham A.,
Tuan J.,
Saris C.,
Elliott G.,
Ma W.,
Benchimol S.,
Lowe S.W.,
Mak T.W.,
Thukral S.K.;
"Characterization of cells and gene-targeted mice deficient for the p53-binding kinase homeodomain-interacting protein kinase 1 (HIPK1).";
Proc. Natl. Acad. Sci. U.S.A. 100:5431-5436(2003).
|
[46]
|
INTERACTION WITH CDKN2AIP.
DOI=10.1042/BJ20040337; PubMed=15109303 [NCBI, ExPASy, EBI, Israel, Japan]
Hasan M.K.,
Yaguchi T.,
Minoda Y.,
Hirano T.,
Taira K.,
Wadhwa R.,
Kaul S.C.;
"Alternative reading frame protein (ARF)-independent function of CARF (collaborator of ARF) involves its interactions with p53: evidence for a novel p53-activation pathway and its negative feedback control.";
Biochem. J. 380:605-610(2004).
|
[47]
|
INTERACTION WITH HRMT1L2; EP300 AND CARM1, AND FUNCTION.
DOI=10.1016/j.cell.2004.05.009; PubMed=15186775 [NCBI, ExPASy, EBI, Israel, Japan]
An W.,
Kim J.,
Roeder R.G.;
"Ordered cooperative functions of PRMT1, p300, and CARM1 in transcriptional activation by p53.";
Cell 117:735-748(2004).
|
[48]
|
PHOSPHORYLATION AT THR-55, MUTAGENESIS OF THR-55, AND INTERACTION WITH TAF1.
DOI=10.1016/S1097-2765(04)00123-6; PubMed=15053879 [NCBI, ExPASy, EBI, Israel, Japan]
Li H.-H.,
Li A.G.,
Sheppard H.M.,
Liu X.;
"Phosphorylation on Thr-55 by TAF1 mediates degradation of p53: a role for TAF1 in cell G1 progression.";
Mol. Cell 13:867-878(2004).
|
[49]
|
METHYLATION AT LYS-372, AND MUTAGENESIS OF LYS-372.
DOI=10.1038/nature03117; PubMed=15525938 [NCBI, ExPASy, EBI, Israel, Japan]
Chuikov S.,
Kurash J.K.,
Wilson J.R.,
Xiao B.,
Justin N.,
Ivanov G.S.,
McKinney K.,
Tempst P.,
Prives C.,
Gamblin S.J.,
Barlev N.A.,
Reinberg D.;
"Regulation of p53 activity through lysine methylation.";
Nature 432:353-360(2004).
|
[50]
|
INTERACTION WITH BANP, SUBCELLULAR LOCATION, AND PHOSPHORYLATION AT SER-15.
DOI=10.1074/jbc.M413200200; PubMed=15701641 [NCBI, ExPASy, EBI, Israel, Japan]
Jalota-Badhwar A.,
Singh K.,
Pavithra L.,
Kaul-Ghanekar R.,
Jameel S.,
Chattopadhyay S.;
"Tumor suppressor SMAR1 activates and stabilizes p53 through its arginine-serine-rich motif.";
J. Biol. Chem. 280:16019-16029(2005).
|
[51]
|
METHYLATION AT LYS-370, AND MUTAGENESIS OF LYS-370.
DOI=10.1038/nature05287; PubMed=17108971 [NCBI, ExPASy, EBI, Israel, Japan]
Huang J.,
Perez-Burgos L.,
Placek B.J.,
Sengupta R.,
Richter M.,
Dorsey J.A.,
Kubicek S.,
Opravil S.,
Jenuwein T.,
Berger S.L.;
"Repression of p53 activity by Smyd2-mediated methylation.";
Nature 444:629-632(2006).
|
[52]
|
MOTIF, AND METHYLATION AT LYS-372.
DOI=10.1038/nsmb1045; PubMed=16415881 [NCBI, ExPASy, EBI, Israel, Japan]
Couture J.-F.,
Collazo E.,
Hauk G.,
Trievel R.C.;
"Structural basis for the methylation site specificity of SET7/9.";
Nat. Struct. Mol. Biol. 13:140-146(2006).
|
[53]
|
INTERACTION WITH WWOX, AND MUTAGENESIS OF SER-46.
DOI=10.1074/jbc.M505590200; PubMed=16219768 [NCBI, ExPASy, EBI, Israel, Japan]
Chang N.-S.,
Doherty J.,
Ensign A.,
Schultz L.,
Hsu L.-J.,
Hong Q.;
"WOX1 is essential for tumor necrosis factor-, UV light-, staurosporine-, and p53-mediated cell death, and its tyrosine 33-phosphorylated form binds and stabilizes serine 46-phosphorylated p53.";
J. Biol. Chem. 280:43100-43108(2005).
|
[54]
|
PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-392, AND MASS SPECTROMETRY.
DOI=10.1021/pr050048h; PubMed=16083285 [NCBI, ExPASy, EBI, Israel, Japan]
Kim J.-E.,
Tannenbaum S.R.,
White F.M.;
"Global phosphoproteome of HT-29 human colon adenocarcinoma cells.";
J. Proteome Res. 4:1339-1346(2005).
|
[55]
|
UBIQUITINATION, INTERACTION WITH SYVN1, AND SUBCELLULAR LOCATION.
DOI=10.1038/sj.emboj.7601490; PubMed=17170702 [NCBI, ExPASy, EBI, Israel, Japan]
Yamasaki S.,
Yagishita N.,
Sasaki T.,
Nakazawa M.,
Kato Y.,
Yamadera T.,
Bae E.,
Toriyama S.,
Ikeda R.,
Zhang L.,
Fujitani K.,
Yoo E.,
Tsuchimochi K.,
Ohta T.,
Araya N.,
Fujita H.,
Aratani S.,
Eguchi K.,
Komiya S., ![]()
Maruyama I.,
Higashi N.,
Sato M.,
Senoo H.,
Ochi T.,
Yokoyama S.,
Amano T.,
Kim J.,
Gay S.,
Fukamizu A.,
Nishioka K.,
Tanaka K.,
Nakajima T.;
"Cytoplasmic destruction of p53 by the endoplasmic reticulum-resident ubiquitin ligase 'Synoviolin'.";
EMBO J. 26:113-122(2007).
|
[56]
|
REVIEW ON ZINC-BINDING PROPERTIES.
DOI=10.1089/15230860152542961; PubMed=11554448 [NCBI, ExPASy, EBI, Israel, Japan]
Hainaut P.,
Mann K.;
"Zinc binding and redox control of p53 structure and function.";
Antioxid. Redox Signal. 3:611-623(2001).
|
[57]
|
PHOSPHORYLATION AT SER-9.
DOI=10.1016/j.febslet.2007.11.022; PubMed=18022393 [NCBI, ExPASy, EBI, Israel, Japan]
Arai S.,
Matsushita A.,
Du K.,
Yagi K.,
Okazaki Y.,
Kurokawa R.;
"Novel homeodomain-interacting protein kinase family member, HIPK4, phosphorylates human p53 at serine 9.";
FEBS Lett. 581:5649-5657(2007).
|
[58]
|
PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-315, AND MASS SPECTROMETRY.
DOI=10.1073/pnas.0611217104; PubMed=17287340 [NCBI, ExPASy, EBI, Israel, Japan]
Molina H.,
Horn D.M.,
Tang N.,
Mathivanan S.,
Pandey A.;
"Global proteomic profiling of phosphopeptides using electron transfer dissociation tandem mass spectrometry.";
Proc. Natl. Acad. Sci. U.S.A. 104:2199-2204(2007).
|
[59]
|
PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-99, AND MASS SPECTROMETRY.
DOI=10.1126/science.1140321; PubMed=17525332 [NCBI, ExPASy, EBI, Israel, Japan]
Matsuoka S.,
Ballif B.A.,
Smogorzewska A.,
McDonald E.R. III,
Hurov K.E.,
Luo J.,
Bakalarski C.E.,
Zhao Z.,
Solimini N.,
Lerenthal Y.,
Shiloh Y.,
Gygi S.P.,
Elledge S.J.;
"ATM and ATR substrate analysis reveals extensive protein networks responsive to DNA damage.";
Science 316:1160-1166(2007).
|
[60]
|
STRUCTURE BY NMR OF 319-360.
PubMed=8023159 [NCBI, ExPASy, EBI, Israel, Japan]
Clore G.M.,
Omichinski J.G.,
Sakaguchi K.,
Zambrano N.,
Sakamoto H.,
Appella E.,
Gronenborn A.M.;
"High-resolution structure of the oligomerization domain of p53 by multidimensional NMR.";
Science 265:386-391(1994).
|
[61]
|
STRUCTURE BY NMR OF 325-355.
DOI=10.1038/nsb1294-877; PubMed=7773777 [NCBI, ExPASy, EBI, Israel, Japan]
Lee W.,
Harvey T.S.,
Yin Y.,
Yau P.,
Litchfield D.,
Arrowsmith C.H.;
"Solution structure of the tetrameric minimum transforming domain of p53.";
Nat. Struct. Biol. 1:877-890(1994).
|
[62]
|
STRUCTURE BY NMR OF 326-354.
DOI=10.1093/emboj/16.20.6230; PubMed=9321402 [NCBI, ExPASy, EBI, Israel, Japan]
McCoy M.,
Stavridi E.S.,
Waterman J.L.,
Wieczorek A.M.,
Opella S.J.,
Halazonetis T.D.;
"Hydrophobic side-chain size is a determinant of the three-dimensional structure of the p53 oligomerization domain.";
EMBO J. 16:6230-6236(1997).
|
[63]
|
X-RAY CRYSTALLOGRAPHY (2.2 ANGSTROMS) OF 94-289.
PubMed=8023157 [NCBI, ExPASy, EBI, Israel, Japan]
Cho Y.,
Gorina S.,
Jeffrey P.D.,
Pavletich N.P.;
"Crystal structure of a p53 tumor suppressor-DNA complex: understanding tumorigenic mutations.";
Science 265:346-355(1994).
|
[64]
|
X-RAY CRYSTALLOGRAPHY (1.7 ANGSTROMS) OF 325-356.
PubMed=7878469 [NCBI, ExPASy, EBI, Israel, Japan]
Jeffrey P.D.,
Gorina S.,
Pavletich N.P.;
"Crystal structure of the tetramerization domain of the p53 tumor suppressor at 1.7 angstroms.";
Science 267:1498-1502(1995).
|
[65]
|
X-RAY CRYSTALLOGRAPHY (2.3 ANGSTROMS) OF 13-29 IN COMPLEX WITH MDM2.
DOI=10.1126/science.274.5289.948; PubMed=8875929 [NCBI, ExPASy, EBI, Israel, Japan]
Kussie P.H.,
Gorina S.,
Marechal V.,
Elenbaas B.,
Moreau J.,
Levine A.J.,
Pavletich N.P.;
"Structure of the MDM2 oncoprotein bound to the p53 tumor suppressor transactivation domain.";
Science 274:948-953(1996).
|
[66]
|
X-RAY CRYSTALLOGRAPHY (2.2 ANGSTROMS) OF 97-287 IN COMPLEX WITH 53BP2.
DOI=10.1126/science.274.5289.1001; PubMed=8875926 [NCBI, ExPASy, EBI, Israel, Japan]
Gorina S.,
Pavletich N.P.;
"Structure of the p53 tumor suppressor bound to the ankyrin and SH3 domains of 53BP2.";
Science 274:1001-1005(1996).
|
[67]
|
X-RAY CRYSTALLOGRAPHY (1.6 ANGSTROMS) OF 358-367 IN COMPLEX WITH USP7, AND INTERACTION WITH USP7.
DOI=10.1038/nsmb1067; PubMed=16474402 [NCBI, ExPASy, EBI, Israel, Japan]
Sheng Y.,
Saridakis V.,
Sarkari F.,
Duan S.,
Wu T.,
Arrowsmith C.H.,
Frappier L.;
"Molecular recognition of p53 and MDM2 by USP7/HAUSP.";
Nat. Struct. Mol. Biol. 13:285-291(2006).
|
[68]
|
X-RAY CRYSTALLOGRAPHY (1.65 ANGSTROMS) OF 360-368 IN COMPLEX WITH USP7, MUTAGENESIS OF PRO-359; GLY-361 AND SER-362, AND INTERACTION WITH USP7.
DOI=10.1371/journal.pbio.0040027; PubMed=16402859 [NCBI, ExPASy, EBI, Israel, Japan]
Hu M.,
Gu L.,
Li M.,
Jeffrey P.D.,
Gu W.,
Shi Y.;
"Structural basis of competitive recognition of p53 and MDM2 by HAUSP/USP7: implications for the regulation of the p53-MDM2 pathway.";
PLoS Biol. 4:228-239(2006).
|
[69]
|
REVIEW.
PubMed=8266092 [NCBI, ExPASy, EBI, Israel, Japan]
Harris C.C.;
"p53: at the crossroads of molecular carcinogenesis and risk assessment.";
Science 262:1980-1981(1993).
|
[70]
|
REVIEW ON VARIANTS.
PubMed=1905840 [NCBI, ExPASy, EBI, Israel, Japan]
Hoolstein M.,
Sidransky D.,
Vogelstein B.,
Harris C.C.;
"p53 mutations in human cancers.";
Science 253:49-53(1991).
|
[71]
|
REVIEW ON VARIANTS.
DOI=10.1002/(SICI)1098-1004(1996)7:3<202::AID-HUMU4>3.3.CO;2-5; PubMed=8829653 [NCBI, ExPASy, EBI, Israel, Japan]
de Vries E.M.G.,
Ricke D.O.,
de Vries T.N.,
Hartmann A.,
Blaszyk H.,
Liao D.,
Soussi T.,
Kovach J.S.,
Sommer S.S.;
"Database of mutations in the p53 and APC tumor suppressor genes designed to facilitate molecular epidemiological analyses.";
Hum. Mutat. 7:202-213(1996).
|
[72]
|
VARIANT ARG-72.
DOI=10.1007/BF00201836; PubMed=1999338 [NCBI, ExPASy, EBI, Israel, Japan]
Olschwang S.,
Laurent-Puig P.,
Vassal A.,
Salmon R.-J.,
Thomas G.;
"Characterization of a frequent polymorphism in the coding sequence of the Tp53 gene in colonic cancer patients and a control population.";
Hum. Genet. 86:369-370(1991).
|
[73]
|
VARIANT LFS THR-133.
PubMed=1933902 [NCBI, ExPASy, EBI, Israel, Japan]
Law J.C.,
Strong L.C.,
Chidambaram A.,
Ferrell R.E.;
"A germ line mutation in exon 5 of the p53 gene in an extended cancer family.";
Cancer Res. 51:6385-6387(1991).
|
[74]
|
VARIANTS LFS CYS-245; TRP-248; PRO-252 AND LYS-258.
PubMed=1978757 [NCBI, ExPASy, EBI, Israel, Japan]
Malkin D.,
Li F.P.,
Strong L.C.,
Fraumeni J.F. Jr.,
Nelson C.E.,
Kim D.H.,
Kassel J.,
Gryka M.A.,
Bischoff F.Z.,
Tainsky M.A.,
Friend S.H.;
"Germ line p53 mutations in a familial syndrome of breast cancer, sarcomas, and other neoplasms.";
Science 250:1233-1238(1990).
|
[75]
|
VARIANT LFS ASP-245.
DOI=10.1038/348747a0; PubMed=2259385 [NCBI, ExPASy, EBI, Israel, Japan]
Srivastava S.,
Zou Z.,
Pirollo K.,
Blattner W.,
Chang E.H.;
"Germ-line transmission of a mutated p53 gene in a cancer-prone family with Li-Fraumeni syndrome.";
Nature 348:747-749(1990).
|
[76]
|
VARIANT LFS LEU-272.
PubMed=1737852 [NCBI, ExPASy, EBI, Israel, Japan]
Felix C.A.,
Nau M.M.,
Takahashi T.,
Mitsudomi T.,
Chiba I.,
Poplack D.G.,
Reaman G.H.,
Cole D.E.,
Letterio J.J.,
Whang-Peng J.,
Knutsen T.,
Minna J.D.;
"Hereditary and acquired p53 gene mutations in childhood acute lymphoblastic leukemia.";
J. Clin. Invest. 89:640-647(1992).
|
[77]
|
VARIANTS LFS HIS-273 AND VAL-325.
PubMed=1565144 [NCBI, ExPASy, EBI, Israel, Japan]
Malkin D.,
Jolly K.W.,
Barbier N.,
Look A.T.,
Friend S.H.,
Gebhardt M.C.,
Andersen T.I.,
Boerresen A.-L.,
Li F.P.,
Garber J.,
Strong L.C.;
"Germline mutations of the p53 tumor-suppressor gene in children and young adults with second malignant neoplasms.";
N. Engl. J. Med. 326:1309-1315(1992).
|
[78]
|
VARIANTS BREAST TUMORS GLN-132; SER-249; LYS-280 AND LYS-285.
PubMed=1694291 [NCBI, ExPASy, EBI, Israel, Japan]
Bartek J.,
Iggo R.,
Gannon J.,
Lane D.P.;
"Genetic and immunochemical analysis of mutant p53 in human breast cancer cell lines.";
Oncogene 5:893-899(1990).
|
[79]
|
VARIANTS COLON TUMORS PHE-241 AND HIS-273.
PubMed=1699228 [NCBI, ExPASy, EBI, Israel, Japan]
Rodrigues N.R.,
Rowan A.,
Smith M.E.F.,
Kerr I.B.,
Bodmer W.F.,
Gannon J.V.,
Lane D.P.;
"p53 mutations in colorectal cancer.";
Proc. Natl. Acad. Sci. U.S.A. 87:7555-7559(1990).
|
[80]
|
VARIANTS ESOPHAGUS TUMOR VAL-154; VAL-245; GLN-248; LEU-278 AND SER-278.
PubMed=2263646 [NCBI, ExPASy, EBI, Israel, Japan]
Hollstein M.C.,
Metcalf R.A.,
Welsh J.A.,
Montesano R.,
Harris C.C.;
"Frequent mutation of the p53 gene in human esophageal cancer.";
Proc. Natl. Acad. Sci. U.S.A. 87:9958-9961(1990).
|
[81]
|
VARIANTS COLORECTAL CANCER MUTATIONS.
DOI=10.1016/0006-291X(91)90623-F; PubMed=1647768 [NCBI, ExPASy, EBI, Israel, Japan]
Ishioka C.,
Sato T.,
Gamoh M.,
Suzuki T.,
Shibata H.,
Kanamaru R.,
Wakui A.,
Yamazaki T.;
"Mutations of the P53 gene, including an intronic point mutation, in colorectal tumors.";
Biochem. Biophys. Res. Commun. 177:901-906(1991).
|
[82]
|
VARIANTS ESOPHAGUS TUMORS LEU-152; ALA-155; HIS-175; PHE-176 AND HIS-273.
PubMed=1868473 [NCBI, ExPASy, EBI, Israel, Japan]
Casson A.G.,
Mukhopadhyay T.,
Cleary K.R.,
Ro J.Y.,
Levin B.,
Roth J.A.;
"p53 gene mutations in Barrett's epithelium and esophageal cancer.";
Cancer Res. 51:4495-4499(1991).
|
[83]
|
VARIANTS HEPATOCELLULAR CARCINOMAS MUTATIONS IN CHINA.
DOI=10.1038/350427a0; PubMed=1849234 [NCBI, ExPASy, EBI, Israel, Japan]
Hsu I.C.,
Metcalf R.A.,
Sun T.,
Welsh J.A.,
Wang N.J.,
Harris C.C.;
"Mutational hotspot in the p53 gene in human hepatocellular carcinomas.";
Nature 350:427-428(1991).
|
[84]
|
VARIANTS HEPATOCELLULAR CARCINOMAS MUTATIONS IN SOUTH AFRICA.
DOI=10.1038/350429a0; PubMed=1672732 [NCBI, ExPASy, EBI, Israel, Japan]
Bressac B.,
Kew M.,
Wands J.,
Ozturk M.;
"Selective G to T mutations of p53 gene in hepatocellular carcinoma from southern Africa.";
Nature 350:429-431(1991).
|
[85]
|
VARIANTS HNSCC PHE-176; PHE-242; CYS-245; LEU-248 AND HIS-273.
PubMed=1394225 [NCBI, ExPASy, EBI, Israel, Japan]
Somers K.D.,
Merrick M.A.,
Lopez M.E.,
Incognito L.S.,
Schechter G.L.,
Casey G.;
"Frequent p53 mutations in head and neck cancer.";
Cancer Res. 52:5997-6000(1992).
|
[86]
|
VARIANTS ANOGENITAL CARCINOMAS.
PubMed=1327751 [NCBI, ExPASy, EBI, Israel, Japan]
Crook T.,
Vousden K.H.;
"Properties of p53 mutations detected in primary and secondary cervical cancers suggest mechanisms of metastasis and involvement of environmental carcinogens.";
EMBO J. 11:3935-3940(1992).
|
[87]
|
VARIANTS ORAL SQUAMOUS CELL CARCINOMA CYS-205; GLU-281 AND LYS-285.
PubMed=1459726 [NCBI, ExPASy, EBI, Israel, Japan]
Sakai E.,
Rikimaru K.,
Ueda M.,
Matsumoto Y.,
Ishii N.,
Enomoto S.,
Yamamoto H.,
Tsuchida N.;
"The p53 tumor-suppressor gene and ras oncogene mutations in oral squamous-cell carcinoma.";
Int. J. Cancer 52:867-872(1992).
|
[88]
|
VARIANT PRO-HIS-PRO-178 INS.
DOI=10.1093/hmg/1.3.207; PubMed=1303181 [NCBI, ExPASy, EBI, Israel, Japan]
Bhatia K.,
Guiterrez M.I.,
Magrath I.T.;
"A novel mutation in the p53 gene in a Burkitt's lymphoma cell line.";
Hum. Mol. Genet. 1:207-208(1992).
|
[89]
|
VARIANTS BURKITT LYMPHOMAS.
PubMed=1437144 [NCBI, ExPASy, EBI, Israel, Japan]
Duthu A.,
Debuire B.,
Romano J.W.,
Ehrhart J.C.,
Fiscella M.,
May E.,
Appella E.,
May P.;
"p53 mutations in Raji cells: characterization and localization relative to other Burkitt's lymphomas.";
Oncogene 7:2161-2167(1992).
|
[90]
|
VARIANT NASOPHARYNGEAL CARCINOMA THR-280.
PubMed=1631151 [NCBI, ExPASy, EBI, Israel, Japan]
Sun Y.,
Hegamyer G.,
Heng Y.-J.,
Hildesheim A.,
Chen J.-Y.,
Chen I.-H.,
Cao Y.,
Yao K.-T.,
Colburn N.H.;
"An infrequent point mutation of the p53 gene in human nasopharyngeal carcinoma.";
Proc. Natl. Acad. Sci. U.S.A. 89:6516-6520(1992).
|
[91]
|
VARIANTS HNSCC.
PubMed=7682763 [NCBI, ExPASy, EBI, Israel, Japan]
Caamano J.,
Zhang S.Y.,
Rosvold E.A.,
Bauer B.,
Klein-Szanto A.J.P.;
"p53 alterations in human squamous cell carcinomas and carcinoma cell lines.";
Am. J. Pathol. 142:1131-1139(1993).
|
[92]
|
VARIANTS HNSCC.
PubMed=8402617 [NCBI, ExPASy, EBI, Israel, Japan]
Boyle J.O.,
Hakim J.,
Koch W.,
van der Riet P.,
Hruban R.H.,
Roa R.A.,
Correo R.,
Eby Y.J.,
Ruppert J.M.,
Sidransky D.;
"The incidence of p53 mutations increases with progression of head and neck cancer.";
Cancer Res. 53:4477-4480(1993).
|
[93]
|
VARIANTS COLON TUMORS.
PubMed=8336944 [NCBI, ExPASy, EBI, Israel, Japan]
Hamelin R.,
Jego N.,
Laurent-Puig P.,
Vidaud M.,
Thomas G.;
"Efficient screening of p53 mutations by denaturing gradient gel electrophoresis in colorectal tumors.";
Oncogene 8:2213-2220(1993).
|
[94]
|
CHARACTERIZATION OF VARIANT ALA-143.
PubMed=8013454 [NCBI, ExPASy, EBI, Israel, Japan]
Zhang W.,
Guo X.-Y.,
Hu G.-Y.,
Liu W.-B.,
Shay J.W.,
Deisseroth A.B.;
"A temperature-sensitive mutant of human p53.";
EMBO J. 13:2535-2544(1994).
|
[95]
|
VARIANTS LFS HIS-175; ARG-193; GLN-248; CYS-273 AND TYR-275.
PubMed=7887414 [NCBI, ExPASy, EBI, Israel, Japan]
Frebourg T.,
Barbier N.,
Yan Y.-X.,
Garber J.E.,
Dreyfus M.,
Fraumeni J.F. Jr.,
Li F.P.,
Friend S.H.;
"Germ-line p53 mutations in 15 families with Li-Fraumeni syndrome.";
Am. J. Hum. Genet. 56:608-615(1995).
|
[96]
|
VARIANT LFS HIS-175.
PubMed=8825920 [NCBI, ExPASy, EBI, Israel, Japan]
Varley J.M.,
McGrown G.,
Thorncroft M.,
Tricker K.J.,
Teare M.D.,
Santibanez-Koref M.F.,
Houlston R.S.,
Martin J.,
Birch J.M.,
Evans D.G.R.;
"An extended Li-Fraumeni kindred with gastric carcinoma and a codon 175 mutation in TP53.";
J. Med. Genet. 32:942-945(1995).
|
[97]
|
VARIANTS ESOPHAGEAL ADENOCARCINOMA PHE-176; SER-245; TRP-248; TRP-282 AND GLN-286.
DOI=10.1002/(SICI)1098-1004(1996)7:2<109::AID-HUMU4>3.3.CO;2-0; PubMed=8829627 [NCBI, ExPASy, EBI, Israel, Japan]
Audrezet M.-P.,
Robaszkiewicz M.,
Mercier B.,
Nousbaum J.-B.,
Hardy E.,
Bail J.-P.,
Volant A.,
Lozac'H P.,
Gouerou H.,
Ferec C.;
"Molecular analysis of the TP53 gene in Barrett's adenocarcinoma.";
Hum. Mutat. 7:109-113(1996).
|
[98]
|
VARIANTS COLORECTAL TUMORS.
DOI=10.1002/(SICI)1098-1004(1997)9:4<348::AID-HUMU8>3.3.CO;2-7; PubMed=9101296 [NCBI, ExPASy, EBI, Israel, Japan]
Guldberg P.,
Nedergaard T.,
Nielsen H.J.,
Olsen A.C.,
Ahrenkiel V.,
Zeuthen J.;
"Single-step DGGE-based mutation scanning of the p53 gene: application to genetic diagnosis of colorectal cancer.";
Hum. Mutat. 9:348-355(1997).
|
|
ExPASy Home page